[1]李卫国,韩 晶,陶 凌,等.血流储备临界值时单纯左前降支中度狭窄患者治疗方案临床研究[J].陕西医学杂志,2021,50(4):450-453.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.017]
　LI Weiguo,HAN Jing,TAO Ling,et al.The choice of treatment scheme of critical value of blood flow reserve in patients with moderate stenosis of left anterior descending artery[J].,2021,50(4):450-453.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.017]
点击复制

血流储备临界值时单纯左前降支中度狭窄患者治疗方案临床研究

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年4期
页码:
450-453
栏目:
临床研究
出版日期:
2021-04-05

文章信息/Info

Title:
The choice of treatment scheme of critical value of blood flow reserve in patients with moderate stenosis of left anterior descending artery
作者:
李卫国; 韩 晶; 陶 凌; 高好考
(空军军医大学西京医院心血管内科,陕西 西安 710032)
Author(s):
LI Weiguo; HAN Jing; TAO Ling; GAO Haokao
(Department of Cardiovascular Medicine,Xijing Hospital,Air Force Medical University,Xi'an 710032,China)
关键词:
动脉粥样硬化;  血流储备分数;  分叉病变;  经皮冠状动脉介入治疗;  Gensini;  心血管事件
Keywords:
Atherosclerosis;  Blood flow reserve fraction;  Bifurcation disease;  PCI;  Gensini;  Cardiovascular event
分类号:
R 541.4
DOI:
DOI:10.3969/j.issn.1000-7377.2021.04.017
文献标志码:
A
摘要:
目的:评估不同治疗方案对血流储备临界值时单纯左前降支中度狭窄患者预后的临床意义。方法: 分析通过冠脉造影确诊冠状动脉粥样硬化心脏病患者,且为单纯左前降支中度狭窄血流储备分数(FFR)值处于0.75～0.80之间的患者73例。根据治疗方案,分为经皮冠状动脉介入治疗(PCI)组(43例)、药物组(30例)。通过评估患者基线资料如血清低密度脂蛋白、血尿酸、C反应蛋白等水平,同时统计患者直径狭窄百分比(DS)、面积狭窄百分比(AS)、参考血管直径(RVD)、最小管腔直径(MLD)以及病变长度(LL)等,同时根据心血管事件发生率、Gensini评分等,评估两种治疗方案临床意义。结果:治疗前,两组间一般资料比较,通过冠脉造影发现,Gensini、DS、AS、RVD、MLD水平,差异无统计学意义(均P>0.05),两组之间具有可比性; 治疗后比较治疗前一般资料水平及DS、AS、RVD、MLD等较前有所好转(均P<0.05),但治疗后两组间差异无统计学意义(均P>0.05); 治疗后1年内,PCI组相比药物组发生不良事件发生率更高(P<0.05)。结论: PCI与药物治疗在短时间内心血管发生事件、严重程度改善方面,无明显差异:相比PCI治疗,药物组更安全。
Abstract:
Objective:To evaluate the clinical significance of different treatment schemes in the prognosis of patients with moderate stenosis of left anterior descending artery.Methods:73 patients with coronary atherosclerotic heart disease diagnosed by coronary angiography were analyzed,and the FFR value of moderate stenosis of left anterior descending artery was 0.75-0.80.According to the treatment plan,the patients were divided into PCI group(43 cases)and drug group(30 cases).According to the baseline data of patients such as serum LDL,serum uric acid,C-reactive protein,the percentage of diameter stenosis(DS),the percentage of area stenosis(AS),the reference vessel diameter(RVD),the minimum lumen diameter(MLD)and the length of lesions(LL)were calculated.At the same time,according to the incidence of cardiovascular events and the Gensini score,the clinical significance of the two treatment methods were evaluated.Results:Before treatment,there was no significant difference in general data,Gensini score,DS,AS,RVD and MLD between the two groups(all P>0.05).After treatment,the general data level and DS,AS,RVD and MLD were improved,but there was no significant difference between the two groups(all P>0.05).Within 1 year after treatment,the incidence of adverse events in PCI group was higher than that in drug group(P<0.05).Conclusion:There was no significant difference in short-term cardiovascular events and severity improvement between PCI and drug therapy.Compared with PCI,drug group was safer.

参考文献/References:

[1] Zhang X,Li Y,Wang Y,et al.Contribution of serum lipids as effect modifiers to a relationship between mean arterial pressure and coronary heart disease in Chinese rural population:The henan rural cohort study[J].BMJ Open,2019,9(11):e29179.
[2] Iadecola C.Revisiting atherosclerosis and dementia[J].Nat Neurosci,2020,23(6):691-692.
[3] Xiang QY,Tian F,Lin QZ,et al.Comparison of remnant cholesterol levels estimated by calculated and measured LDL-C levels in Chinese patients with coronary heart disease[J].Clin Chim Acta,2020,500:75-80.
[4] 刘子歌,刘 洋,宋国瑞,等.泡沫细胞在动脉粥样硬化形成过程中的作用研究进展[J].陕西医学杂志,2020,49(10):1363-1366.
[5] Johnson JL.Metalloproteinases in atherosclerosis[J].Eur J Pharmacol,2017,816:93-106.
[6] Spinelli FR,Barone F,Cacciapaglia F,et al.Atherosclerosis and autoimmunity[J].Mediators Inflamm,2018,2018:6730421.
[7] 刘 娟,郑小军,肖 飞,等.青年脑梗死患者颈动脉粥样硬化与Hcy、hs-CRP及CysC相关性研究[J].陕西医学杂志,2017,46(1):43-45.
[8] 赵红敏,袁山旗,庞苗苗.颈动脉多普勒彩色超声联合脂联素和白细胞介素-8检测在动脉粥样硬化中应用价值研究[J].陕西医学杂志,2019,48(1):64-66.
[9] Fernandez-Ruiz I.Redefining leukocytes in atherosclerosis[J].Nat Rev Cardiol,2018,15(6):319.
[10] Siegel D,Devaraj S,Mitra A,et al.Inflammation,atherosclerosis,and psoriasis[J].Clin Rev Allergy Immunol,2013,44(2):194-204.
[11] Kennedy MW,Hermanides RS,Kaplan E,et al.Fractional flow reserve-guided deferred versus complete revascularization in patients with diabetes mellitus[J].Am J Cardiol,2016,118(9):1293-1299.
[12] Sarmah D,Datta A,Raut S,et al.Role of Inflammasomes in atherosclerosis and stroke pathogenesis[J].Curr Pharm Des,2020,4:26-34.
[13] Sargolzaei J,Chamani E,Kazemi T,et al.The role of adiponectin and adipolin as anti-inflammatory adipokines in the formation of macrophage foam cells and their association with cardiovascular diseases[J].Clin Biochem,2018,54:1-10.
[14] Joh JH,Cho S.Cardiovascular risk of carotid atherosclerosis:Global consensus beyond societal guidelines[J].Lancet Glob Health,2020,8(5):e625-e626.
[15] 赵红敏,袁山旗,庞苗苗.颈动脉多普勒彩色超声联合脂联素和白细胞介素-8检测在动脉粥样硬化中应用价值研究[J].陕西医学杂志,2019,48(1):64-66.
[16] He X,Matam BR,Bellary S,et al.CHD risk minimization through lifestyle control:Machine learning gateway[J].Sci Rep,2020,10(1):4090.
[17] Owsiany KM,Alencar GF,Owens GK.Revealing the origins of foam cells in atherosclerotic lesions[J].Arterioscler Thromb Vasc Biol,2019,39(5):836-838.
[18] Dalbeni A,Giollo A,Bevilacqua M,et al.Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients[J].Hypertens Res,2017,236:488-492.
[19] Lee JM,Koo BK,Shin ES,et al.Clinical implications of three-vessel fractional flow reserve measurement in patients with coronary artery disease[J].Eur Heart J,2018,39(11):945-951.
[20] 杨晓飞,王彩虹,栾荣华.心脏导管介入术后中风发病率及危险因素分析[J].陕西医学杂志,2015,44(7):812-815.

相似文献/References:

[1]陈文璐,张 婧,徐晓辉△.加倍剂量阿托伐他汀钙对稳定型心绞痛患者血清[J].陕西医学杂志,2018,(12):1548.
[2]赵红敏,袁山旗△,庞苗苗.颈动脉多普勒彩色超声联合脂联素和白细胞介素8检测在动脉粥样硬化中应用价值研究[J].陕西医学杂志,2019,(1):64.
[3]张 喆,马 鹏.幽门螺旋杆菌感染与动脉粥样硬化关系的研究进展[J].陕西医学杂志,2019,(2):270.
[4]何春艳,裴美娟,李玉明,等.发状分裂增强子1对胆固醇刺激下内皮细胞的影响及机制研究[J].陕西医学杂志,2023,52(9):1115.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.001]
　HE Chunyan,PEI Meijuan,LI Yuming,et al.Effect and mechanism of HES-1 on cholesterol stimulated endothelial cells[J].,2023,52(4):1115.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.001]
[5]梁 铖,谢玉霞,王新成,等.冠心病患者血清胱抑素C、高敏C反应蛋白、非高密度脂蛋白胆固醇与血流储备分数相关性研究[J].陕西医学杂志,2024,(4):500.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.014]
　LIANG Cheng,XIE Yuxia,WANG Xincheng,et al.Correlation between serum CysC,hs-CRP,non-HDL-C and blood flow reserve fraction in patients with coronary heart disease[J].,2024,(4):500.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.014]
[6]张国安,石践,宋宝国,等.囊泡相关膜蛋白8通过激活AMP活化蛋白激酶/哺乳动物雷帕霉素靶蛋白介导自噬促进动脉粥样硬化研究[J].陕西医学杂志,2025,54(7):899.[doi:DOI:10.3969/j.issn.1000-7377.2025.07.006]
　ZHANG Guoan,SHI Jian,SONG Baoguo,et al.VAMP8 promotes atherosclerosis progression through the AMPK-mTOR pathway mediated autophagy[J].,2025,54(4):899.[doi:DOI:10.3969/j.issn.1000-7377.2025.07.006]
[7]李震,晋群.炎症在冠心病发生发展中的作用及抗炎治疗研究进展[J].陕西医学杂志,2025,54(7):1001.[doi:DOI:10.3969/j.issn.1000-7377.2025.07.026]
[8]谢佳佳,廖文君,吴碧君,等.秋水仙碱对动脉粥样硬化小鼠主动脉斑块的干预作用及对核苷酸结合寡聚化结构域样受体3/含CARD结构域的凋亡相关颗粒样蛋白/含半胱氨酸的天冬氨酸蛋白酶1信号通路、炎症反应的影响[J].陕西医学杂志,2025,54(10):1324.[doi:DOI:10.3969/j.issn.1000-7377.2025.10.005]
　XIE Jiajia,LIAO Wenjun,WU Bijun,et al.Intervention effect of colchicine on aortic plaque in atherosclerosis mice and the influence on NLRP3/ASC/Caspase-1 signal pathway and inflammatory response[J].,2025,54(4):1324.[doi:DOI:10.3969/j.issn.1000-7377.2025.10.005]
[9]高兰,黄哲凯,寇俊萍,等.脂肪因子在心血管疾病中的研究进展[J].陕西医学杂志,2026,(4):561.[doi:DOI:10.3969/j.issn.1000-7377.2026.04.023]
　GAO Lan,HUANG Zhekai,KOU Junping,et al.Research progress on the role of adipokines in cardiovascular diseases[J].,2026,(4):561.[doi:DOI:10.3969/j.issn.1000-7377.2026.04.023]
[10]高兰,林洋洋,陈宏,等.线粒体自噬在心血管疾病中的研究进展[J].陕西医学杂志,2026,(7):996.[doi:DOI:10.3969/j.issn.1000-7377.2026.07.022]
　GAO Lan,LIN Yangyang,CHEN Hong,et al.Research progress on role and mechanism of mitochondrial autophagy in cardiovascular diseases[J].,2026,(4):996.[doi:DOI:10.3969/j.issn.1000-7377.2026.07.022]

更新日期/Last Update: 2021-04-06